0.10Open0.10Pre Close0 Volume160 Open Interest20.00Strike Price0.00Turnover68.35%IV35.90%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier31DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.0809Delta0.0509Gamma147.90Leverage Ratio-0.0072Theta0.0009Rho11.96Eff Leverage0.0065Vega
Grail Stock Discussion
Larger Image: tradingview.com...
$Grail (GRAL.US)$
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet